Literature DB >> 8198992

Expression of ras oncogene p21 protein in normal and neoplastic laryngeal tissues: correlation with histopathological features and epidermal growth factor receptors.

G Scambia1, L Catozzi, P Benedetti Panici, G Ferrandina, G Almadori, G Paludetti, G Cadoni, M Distefano, A Piffanelli, S Mancuso.   

Abstract

Western blotting analysis of the p21 ras oncoprotein was performed in seven normal laryngeal mucosa specimens and 43 primary laryngeal cancers. Varying p21 levels, expressed as optical density (OD), were found in normal mucosa (median 1.94 OD, range 0.90-2.17 OD) and in primary laryngeal tumours (median 1.74 OD, range 0.30-6.37 OD). When p21 expression in laryngeal cancer was compared with the normal counterpart, higher levels were found in neoplastic than in normal laryngeal tissue (median 2.54 OD, range 1.76-6.37 OD, vs median 1.94 OD, range 0.90-2.17 OD) (P = 0.023). Immunohistochemical analysis demonstrated that most of the tumour cells (more than 70%) were immunostained while the stromal component was unreactive. No correlation between p21 expression and tumour location, stage and histopathological grade was observed. The correlation between ras p21 protein expression and epidermal growth factor receptor (EGFR) levels was also investigated. EGFR-positive cases did not show any difference in p21 expression with respect to EGFR-negative cases (median 1.52 OD, range 0.30-6.37 OD, vs median 1.84 OD, range 0.93-3.71 OD). Our findings suggest that overexpression of p21 protein is associated with a malignant phenotype in laryngeal cancer. Further studies should be undertaken to evaluate whether the assessment of p21 protein expression may have clinical significance in laryngeal cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8198992      PMCID: PMC1969458          DOI: 10.1038/bjc.1994.195

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  32 in total

Review 1.  Oncogenes, molecular biology and the head and neck surgeon.

Authors:  J C Irish
Journal:  J Otolaryngol       Date:  1992-12

2.  Homologous activators of ras in fission and budding yeast.

Authors:  D A Hughes; Y Fukui; M Yamamoto
Journal:  Nature       Date:  1990-03-22       Impact factor: 49.962

3.  Oncogene amplification in squamous cell carcinoma of the head and neck.

Authors:  W D Merritt; M C Weissler; B F Turk; T M Gilmer
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1990-12

4.  Expression of ras p21 oncoprotein in normal and neoplastic human endometrium.

Authors:  G Scambia; L Catozzi; P Benedetti-Panici; G Ferrandina; F Battaglia; G Giovannini; M Distefano; D Pellizzola; A Piffanelli; S Mancuso
Journal:  Gynecol Oncol       Date:  1993-09       Impact factor: 5.482

5.  Immunohistochemical detection of ras 21 in oral squamous cell carcinomas.

Authors:  M Satoh; S Hatakeyama; M Sashima; A Suzuki
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1992-10

6.  EGF receptor expression in primary laryngeal cancer: correlation with clinico-pathological features and prognostic significance.

Authors:  M Maurizi; G Scambia; P Benedetti Panici; G Ferrandina; G Almadori; G Paludetti; R De Vincenzo; M Distefano; D Brinchi; G Cadoni
Journal:  Int J Cancer       Date:  1992-12-02       Impact factor: 7.396

7.  Expression of ras oncogene p21 protein in normal and neoplastic ovarian tissues: correlation with histopathologic features and receptors for estrogen, progesterone, and epidermal growth factor.

Authors:  G Scambia; L Catozzi; P B Panici; G Ferrandina; F Coronetta; R Barozzi; G Baiocchi; L Uccelli; A Piffanelli; S Mancuso
Journal:  Am J Obstet Gynecol       Date:  1993-01       Impact factor: 8.661

8.  Prevalence of RAS oncogene mutation in head and neck carcinomas.

Authors:  J A Anderson; J C Irish; B Y Ngan
Journal:  J Otolaryngol       Date:  1992-10

9.  Analysis of the c-Ha-ras-1 gene for deletion, mutation, amplification and expression in lymph node metastases of human head and neck carcinomas.

Authors:  Z M Sheng; M Barrois; J Klijanienko; C Micheau; J M Richard; G Riou
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

10.  Elevated expression of the human ras oncogene family in premalignant and malignant tumours of the colorectum.

Authors:  D A Spandidos; I B Kerr
Journal:  Br J Cancer       Date:  1984-06       Impact factor: 7.640

View more
  6 in total

Review 1.  Predictive factors of neck metastases in laryngeal squamous cell carcinoma. Towards an integrated clinico-molecular classification.

Authors:  G Almadori; F Bussu; G Paludettii
Journal:  Acta Otorhinolaryngol Ital       Date:  2006-12       Impact factor: 2.124

2.  Prognostic significance of methyl-p-hydroxy-phenyllactate-esterase activity in laryngeal squamous cell carcinoma.

Authors:  M Maurizi; G Ferrandina; G Almadori; G Scambia; G Cadoni; G D'Agostino; F G Serra; M Piantelli; S Mancuso; F O Ranelletti
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

3.  Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma.

Authors:  M Maurizi; G Almadori; G Ferrandina; M Distefano; M E Romanini; G Cadoni; P Benedetti-Panici; G Paludetti; G Scambia; S Mancuso
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

4.  Overexpression of wild-type p21Ras plays a prominent role in colorectal cancer.

Authors:  Shuang Bai; Qiang Feng; Xin-Yan Pan; Hong Zou; Hao-Bin Chen; Peng Wang; Xin-Liang Zhou; Yan-Ling Hong; Shu-Ling Song; Ju-Lun Yang
Journal:  Int J Mol Med       Date:  2017-02-21       Impact factor: 4.101

5.  Mutations, expression and genomic instability of the H-ras proto-oncogene in squamous cell carcinomas of the head and neck.

Authors:  H Kiaris; D A Spandidos; A S Jones; E D Vaughan; J K Field
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

6.  Tumor growth suppressive effect of IL-4 through p21-mediated activation of STAT6 in IL-4Rα overexpressed melanoma models.

Authors:  Hye Lim Lee; Mi Hee Park; Ju Kyoung Song; Yu Yeon Jung; Youngsoo Kim; Kyung Bo Kim; Dae Yeon Hwang; Do Young Yoon; Min Jong Song; Sang Bae Han; Jin Tae Hong
Journal:  Oncotarget       Date:  2016-04-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.